



Summary Report of *Bio Taiwan 2005*

BioTaiwan 2005, the largest biotech conference & exhibition in Asia, kicked off on July 19th with international events including the *APEC Biotechnology Conference*, and *BioBusiness Asia 2005*. The APEC conference discussed regulations and development policies, while *BioBusiness Asia* exchanged ideas and experience amongst industry analysts and international companies. Following these successful events, the *BioTaiwan* exhibition ran from July 22 – 25

DCB president Dr. Julien HUANG, one of the chief organizers of *BioBusiness Asia*, pointed out in her opening remarks that since the establishment of the DCB, it has been instrumental in helping the Taiwan government to develop its biotechnology roadmap. She also stressed that the primary mission of the DCB is to become a center of excellence in research and development, and provide industrial services to local companies so that they can gain access to biotechnology from around the world. She then remarked that through its regular participation in biotech conferences and exhibitions like *Bio USA*, and for the first time, some of the biggest biotech events in Europe, including *BioVision* and the *BioSquare Convention* in Lyon, France, the DCB has entered into partnerships with the international biotech community. While in France, the DCB visited the French government's 'Invest in France Agency', *Institut Pasteur*, and genetic scientific park *Genopole*. Through its interest and participation in the international biotech community, the DCB hopes to build solid partnerships both locally and worldwide.

At *Bio Taiwan 2005*, the DCB's booth attracted both local and international companies, institutions, organizations, and individuals. Some chief international companies and institutions included *PMG*, *Bruker Daltonios*, *Roche*, *Boehringer Ingelheim*, *Foldyne*, *MDS Capital Corp.*, the French Economic Department, the Netherlands Trade and Investment Office, and the Australian Commonwealth Scientific Industrial Research Organization (CSIRO).

They were impressed with our booth which featured:

- * DCB's R&D programs and services: pharmaceutical, biopharmaceutical, Chinese herbal medicine, gene-based medicine, environmental biotechnology, CGMP pilot plant, preclinical studies in toxicology

- * Business development promotion services: Biofronts, Nankang Incubation Center, Industrial Technology Intelligence Services (ITIS)

- * Occidental drugs co-developed by DCB and industries: Albuterol Sulfate (MDI) for Asthma

- * Chinese herbal medicines co-developed by DCB and industries: DCB-CA1 for Cancer Adjuvant; DCB-AD1 for Alzheimer's disease; DCB-SLE for Systemic Lupus Erythematosus; DCB-WH1 for wound healing

- * Environmental biotechnology program: Bio-flocculants for waste or polluted water treatment; *Daphnia similis*, water flea for environmental protection and Enzyme drinks etc.

For more information, please contact: elodie.wei@mail.dcb.org.tw
Tel: +886 (0)2 2695 6933 ext. 5313 / Fax: +886 (0)2 6615 1110